Markets
H.C. Wainwright Reiterates Invivyd Buy Rating as Antibody Trial Progress Builds Conviction
H.C. Wainwright has reiterated its bullish stance on Invivyd as clinical trial momentum builds, keeping the biotech firmly on active traders' radars. Here is what the reiteration signals and the specific levels that matter most right now.